NASDAQ:QURE uniQure (QURE) Stock Price, News & Analysis $3.83 -0.08 (-2.05%) (As of 11:08 AM ET) Add Compare Share Share Today's Range$3.73▼$3.9250-Day Range$3.91▼$5.4352-Week Range$3.73▼$11.82Volume160,710 shsAverage Volume814,106 shsMarket Capitalization$185.95 millionP/E RatioN/ADividend YieldN/APrice Target$23.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get uniQure alerts: Email Address uniQure MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside510.1% Upside$23.00 Price TargetShort InterestHealthy5.40% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 6 Articles This WeekInsider TradingSelling Shares$41,534 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.45) to ($3.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.01 out of 5 starsMedical Sector440th out of 896 stocksPharmaceutical Preparations Industry201st out of 424 stocks 3.4 Analyst's Opinion Consensus RatinguniQure has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageuniQure has only been the subject of 2 research reports in the past 90 days.Read more about uniQure's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.40% of the outstanding shares of uniQure have been sold short.Short Interest Ratio / Days to CoveruniQure has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in uniQure has recently decreased by 11.78%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YielduniQure does not currently pay a dividend.Dividend GrowthuniQure does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for QURE. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 6 news articles for uniQure this week, compared to 0 articles on an average week.Search InterestOnly 3 people have searched for QURE on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added uniQure to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, uniQure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $41,534.00 in company stock.Percentage Held by InsidersOnly 4.74% of the stock of uniQure is held by insiders.Percentage Held by Institutions78.83% of the stock of uniQure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about uniQure's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for uniQure are expected to grow in the coming year, from ($4.45) to ($3.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of uniQure is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of uniQure is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatiouniQure has a P/B Ratio of 0.87. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about uniQure's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Oasis GoldNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.Click Here To Get Your FREE Guide Now! About uniQure Stock (NASDAQ:QURE)uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.Read More QURE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart QURE Stock News HeadlinesJuly 5 at 1:22 AM | americanbankingnews.comuniQure (NASDAQ:QURE) Expected to Earn Q3 2024 Earnings of ($1.02) Per ShareJuly 1, 2024 | prnewswire.comGenezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MAJuly 5, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.July 1, 2024 | globenewswire.comuniQure Announces Sale of Commercial Manufacturing Facility to GenezenJune 3, 2024 | globenewswire.comuniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's DiseaseMay 7, 2024 | investorplace.comQURE Stock Earnings: uniQure Misses EPS, Beats Revenue for Q1 2024May 7, 2024 | globenewswire.comuniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company ProgressFebruary 28, 2024 | globenewswire.comuniQure Announces 2023 Financial Results and Highlights Recent Company ProgressJuly 5, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.July 17, 2023 | seekingalpha.comuniQure: The AMT-130 ReadoutMay 22, 2023 | seekingalpha.comMarket Is Still Not Pricing In The FDA And EU EMA Approvals For uniQureMay 20, 2023 | seekingalpha.comuniQure: Financials And Pipeline Signal A Promising Outlook For InvestorsFebruary 7, 2022 | globenewswire.comuniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington's Disease - GlobeNewswireFebruary 7, 2022 | finance.yahoo.comuniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s DiseaseFebruary 5, 2022 | washingtonpost.comWith CRISPR gene editing, unique treatments begin to take off for rare diseases - The Washington PostFebruary 4, 2022 | finance.yahoo.comGlobal Gene Therapy for Blood Disorders Market worth US$ 5.79 Billion by 2030 - Exclusive Report by InsightAce Analytic - Yahoo FinanceFebruary 4, 2022 | marketscreener.comEAHAD 2022 - Final Analysis from the Pivotal Phase 3 HOPE-B Gene Therapy Trial: Stable Steady-State Efficacy and Safety of Etranacogene Dezaparvovec in Adults with Sever or Moderately Severe Hemophilia B - Marketscreener.comFebruary 4, 2022 | axios.com5 unique date ideas in NW Arkansas - AxiosSee More Headlines Receive QURE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/05/2024Next Earnings (Estimated)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:QURE CUSIPN/A CIK1590560 Webwww.uniqure.com Phone(120) 240-6000Fax31-20-566-9272Employees480Year FoundedN/APrice Target and Rating Average Stock Price Target$23.00 High Stock Price Target$50.00 Low Stock Price Target$6.00 Potential Upside/Downside+488.2%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($6.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-308,480,000.00 Net Margins-1,562.22% Pretax Margin-1,542.31% Return on Equity-121.60% Return on Assets-34.76% Debt Debt-to-Equity Ratio0.70 Current Ratio9.39 Quick Ratio9.27 Sales & Book Value Annual Sales$19.00 million Price / Sales9.99 Cash FlowN/A Price / Cash FlowN/A Book Value$4.34 per share Price / Book0.90Miscellaneous Outstanding Shares48,549,000Free Float46,248,000Market Cap$189.83 million OptionableOptionable Beta0.97 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Matthew Craig Kapusta (Age 52)CEO & Executive Director Comp: $1.02MMr. Christian Klemt (Age 51)CFO, Principal Financial Officer & GM of Amsterdam Site Comp: $575.46kMr. Pierre Caloz (Age 52)Chief Operating Officer Comp: $882.59kDr. Tamara Tugal Ph.D.MBA, Business Development DirectorMs. Carla PoulsonInterim Chief People and Culture OfficerMs. Maria E. Cantor (Age 56)Chief Corporate Affairs Officer Comp: $491.12kDr. Amin Abujoub Ph.D.Chief Quality OfficerDr. Walid Abi-Saab M.D. (Age 59)Chief Medical Officer Eileen SawyerVice President of Global Medical AffairsMore ExecutivesKey CompetitorsBicycle TherapeuticsNASDAQ:BCYCTyra BiosciencesNASDAQ:TYRAABIVAX Société AnonymeNASDAQ:ABVXARS PharmaceuticalsNASDAQ:SPRYAurinia PharmaceuticalsNASDAQ:AUPHView All CompetitorsInsiders & InstitutionsWalid Abi-SaabSold 1,447 sharesTotal: $6,308.92 ($4.36/share)Jeannette PottsSold 4,781 sharesTotal: $23,809.38 ($4.98/share)Rachelle Suzanne JacquesSold 2,221 sharesTotal: $11,415.94 ($5.14/share)Ikarian Capital LLCBought 311,768 shares on 5/17/2024Ownership: 0.966%Walleye Trading LLCSold 5,400 shares on 5/17/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions QURE Stock Analysis - Frequently Asked Questions How have QURE shares performed this year? uniQure's stock was trading at $6.77 at the start of the year. Since then, QURE shares have decreased by 43.9% and is now trading at $3.80. View the best growth stocks for 2024 here. How were uniQure's earnings last quarter? uniQure (NASDAQ:QURE) announced its quarterly earnings data on Tuesday, May, 7th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts' consensus estimates of ($1.31) by $0.05. The biotechnology company earned $8.49 million during the quarter, compared to the consensus estimate of $2.58 million. uniQure had a negative net margin of 1,562.22% and a negative trailing twelve-month return on equity of 121.60%. What is Matthew Kapusta's approval rating as uniQure's CEO? 8 employees have rated uniQure Chief Executive Officer Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among the company's employees. How do I buy shares of uniQure? Shares of QURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of uniQure own? Based on aggregate information from My MarketBeat watchlists, some other companies that uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH) and NVIDIA (NVDA). This page (NASDAQ:QURE) was last updated on 7/5/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the star...Chaikin Analytics | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding uniQure Please log in to your account or sign up in order to add this asset to your watchlist. Share uniQure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free QURE Stock Alerts